Remdesivir Dosing for COVID-19 Pneumonia
For a 60 kg inpatient with COVID-19 pneumonia and normal renal function, administer remdesivir 200 mg IV on day 1, followed by 100 mg IV daily for a total of 5 days (5 doses). 1
Dosing Regimen
The standard adult dosing is weight-independent and does not require adjustment for this 60 kg patient with normal kidney function:
- Day 1 (Loading dose): 200 mg IV infusion over 30 minutes
- Days 2-5 (Maintenance): 100 mg IV daily over 30 minutes
Total course duration: 5 days for patients not requiring mechanical ventilation or ECMO 1
Duration Selection: 5-Day vs 10-Day Course
Choose a 5-day course for this patient with COVID-19 pneumonia not requiring mechanical ventilation or ECMO. The evidence shows:
- A 5-day course is as effective as a 10-day course in patients with severe COVID-19 not requiring mechanical ventilation 1
- The 5-day regimen results in fewer adverse events (modest effect) compared to the 10-day course 1
- Reserve the 10-day course only for patients requiring mechanical ventilation or ECMO at baseline 1
Renal Function Considerations
With normal kidney function, no dose adjustment is required 1, 2:
- The FDA recommends assessing kidney function at baseline and during treatment 1
- Remdesivir should not be used if eGFR <30 mL/min/1.73 m² (per older guidance), though recent evidence supports use in all stages of renal impairment 2, 3
- For this patient with normal renal function, proceed with standard dosing
Timing and Clinical Context
Initiate treatment early for optimal benefit:
- Greater benefit observed when started within 10 days of symptom onset 1
- Treatment should be based on clinical judgment; avoid initiating in patients hospitalized for non-COVID-19 reasons who incidentally test positive 4
Monitoring Requirements
Baseline and ongoing monitoring 1, 4:
- Hepatic function: Check ALT/AST at baseline and during treatment
- Discontinue if ALT increases to ≥5× upper limit of normal (older guidance) or >10× upper limit of normal (updated guidance) 4
- Discontinue if ALT elevation accompanied by signs of liver inflammation
- Renal function: Monitor eGFR during treatment
- Watch for hypersensitivity reactions during and after infusion
Common Pitfalls to Avoid
Do not extend to 10 days unless the patient deteriorates to require mechanical ventilation or ECMO—the 5-day course is sufficient for non-ventilated patients 1
Do not adjust dose based on weight—the 200 mg/100 mg regimen is standard for all adults regardless of body weight 1, 2
Do not delay treatment waiting for severe disease progression—earlier initiation (within 10 days of symptoms) yields better outcomes 1
Monitor for infusion-related reactions—hypersensitivity and anaphylactic reactions have been reported 1